Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Neovascular Age-Related Macular Degeneration An Open-Label Extension Study
Led by Hoffmann-La Roche · Updated on 2026-10-27
1000
Participants Needed
165
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are assessing the long-term safety and tolerability of the Port Delivery System with ranibizumab PDS in people with neovascular age-related macular degeneration nAMD who have completed previous related studies or certain visits within those studies. The trial includes two sub-studies to evaluate specific aspects one tests the effectiveness of transscleral photocoagulation to reduce vitreous hemorrhages after PDS implantation, and the other assesses the safety of re-implantation with an updated PDS device.
Participants receive the PDS implant with ranibizumab at a concentration of 100 mgmL, administered through refill-exchange procedures at set intervals varying by previous study involvement, typically every 24 weeks with some switching to every 12 weeks later in the trial. The sub-studies involve additional treatments such as laser therapy or re-implantation and follow-up for up to 72 weeks. Treatment schedules and monitoring differ depending on enrollment cohorts and prior participation.
Throughout the study, participants undergo regular assessments including eye exams, imaging, and monitoring for adverse events related to the PDS implant and ranibizumab treatment. The study tracks vision changes, ocular health, device safety, and any complications over periods up to 240 weeks or longer if regulatory approval is pending. Participants adherence to visit schedules and safety measures are closely observed as part of the trials long-term evaluation.
CONDITIONS
Brief Title
Extension Study for the Port Delivery System With Ranibizumab (Portal)
Research Team
R
Reference Study ID Number: GR40549 https://forpatients.roche.com/ No attachments to email below.
F
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
PDS Implant with Ranibizumab
Standard Intravitreal Anti-VEGF Injections
What it is
A permanent, refillable eye implant that continuously delivers a high-concentration ranibizumab formulation to treat neovascular (wet) age-related macular degeneration.
Intravitreal injections of anti-VEGF medications—ranibizumab, aflibercept, or bevacizumab—delivered directly into the eye at regular intervals.
Primary use
Used to maintain vision and control disease activity in adults with neovascular age-related macular degeneration who previously received PDS treatment in a pivotal trial.
Guideline-recommended long-term therapy for preserving vision and suppressing disease activity in patients with neovascular age-related macular degeneration.
How it is given or performed
Implantation involves a surgical procedure to place the device in the eye, followed by in-clinic refill-exchange procedures of ranibizumab every several months.
Intravitreal anti-VEGF injections are given by an ophthalmologist in a clinic setting, typically every 4 to 12 weeks depending on disease response and agent.
Evidence status
Efficacy and safety are being assessed in ongoing extension follow-up; interim results show durability and visual outcomes consistent with previous pivotal PDS trials.
Supported by decades of randomized clinical trials, meta-analyses, and clinical practice guidelines as the standard long-term therapy for controlling nAMD and maintaining vision.
Important limitations
Potential risks include surgical and device-related complications such as endophthalmitis, vitreous hemorrhage, or device malfunction. Long-term extension data for real-world outcomes are still being collected.
Major limitations include the need for frequent clinic injections, treatment burden, and risks such as endophthalmitis, elevated eye pressure, or retinal complications.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 50Years +
All Genders
Eligibility Criteria
You may qualify if you...
Previously completed Study GX28228 (Ladder) or Study GR40548 (Archway) without early treatment or discontinuation, OR participated in Study WR42221 (Velodrome) and completed or were not eligible for randomization at Week 24
Able and willing to attend all scheduled visits and assessments
For women of childbearing potential: agree to remain abstinent or use contraception
For Sub-study 1: diagnosis of exudative nAMD within 2 years, prior anti-VEGF injections within 6 months, response to prior treatment, clear ocular media, and adequate pupil dilation
For Sub-study 2: experienced septum dislodgement in the original implant and clear ocular media with adequate pupil dilation
You will not qualify if you...
Pregnant, breastfeeding, or planning pregnancy during treatment and for specified periods after last ranibizumab injection or implant refill
History of other ocular diseases or conditions contraindicating ranibizumab or implant use, or increasing risk of complications
Prior ocular surgeries or treatments including vitrectomy, submacular surgery, corticosteroid injections, or intraocular device implantation
Recent use of anti-VEGF agents other than ranibizumab within 1 month prior to enrollment
Certain ocular conditions such as subretinal hemorrhage, fibrosis, atrophy, uveitis, infections, or glaucoma-related surgeries
Uncontrolled systemic diseases, recent stroke or heart attack, active infections, cancer within 12 months, or use of certain systemic therapies
Participation in other investigational drug trials within specified time frames
Specific exclusions for Sub-study 1 and 2 related to ocular conditions, surgeries, infections, and systemic health as detailed in the protocol
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are assessed for eligibility based on prior study participation, eye health, and general health criteria.
1 visit (in-person)
Treatment
Duration - Up to 240 weeks or longer until regulatory approval or study closure
Participants receive the Port Delivery System implant with ranibizumab and undergo refill-exchange procedures at intervals determined by their previous study cohort. Sub-studies include laser treatment or re-implantation with additional follow-up.
Visits every 12 or 24 weeks depending on cohort and study phase
Follow-up
Duration - Up to 72 weeks for sub-studies; ongoing for main study as needed
Participants are monitored for safety, vision changes, and any adverse events related to the implant and treatment. Sub-study participants receive additional assessments for up to 72 weeks after re-implantation or laser treatment.
Regular visits at scheduled intervals
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
11
Similar Trials
Evaluation of a 36-Week Refill Schedule for the Port Delivery System with Ranibizumab in Patients with Neovascular Age-related Macular Degeneration
Randomized Double-Masked Study Comparing ABP 938 and EYLEA48 in Treating Neovascular Age-Related Macular Degeneration with Intravitreal Injections
Phase II Study of Intravitreal IBI302 Injection for Treating Neovascular Age-related Macular Degeneration in Adults 50 and Older
Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Neovascular Age-Related Macular Degeneration An Open-Label Extension Study
Phase 1 and 2 Study Testing FT-003 Gene Therapy for Wet Age-Related Macular Degeneration in Adults Aged 50 to 80
Phase 12 Study Evaluating Safety and Early Effects of SKG0106 Gene Therapy Injection for Neovascular Age-related Macular Degeneration
Post-Marketing Safety and Effectiveness Study of Brolucizumab Beovu Injection and Prefilled Syringe for Neovascular Age-related Macular Degeneration
Evaluating the Safety and Effectiveness of LX111 Gene Therapy Injection for Neovascular Age-related Macular Degeneration in Adults 50 and Older
Phase IIIa Study of Single Subretinal Injection of RRG001 Gene Therapy for Neovascular Age-related Macular Degeneration in Adults Aged 50 and Older
Randomized Study Evaluating Safety, Injection Burden, and Vision Outcomes of Surabgene Lomparvovec Versus Ranibizumab in Adults with Neovascular Age-Related Macular Degeneration